The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease – a phase 1 trial with three doses
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Background: Mesenchymal stromal cells ability to reset immune functionalities may be useful in Crohn's disease. Aim: To perform a first‐in‐human phase 1 safety clinical trial of metabolically fit autologous bone marrow‐derived mesenchymal stromal cells in 12 subjects with Crohn's disease utilising three doses. Methods: Autologous mesenchymal stromal cells were derived from marrow aspirate and propagated for 2–3 weeks with fibrinogen depleted human platelet lysate and subsequently administered to subjects without interval cryobanking. Twelve subjects received a single mesenchymal stromal cell intravenous infusion of 2, 5 or 10 million cells/kg BW(n = 4/group). Infused mesenchymal stromal cells were analysed for cell surface marker expression, IDO(indoleamine 2,3‐dioxygenase) upregulation by IFNγ stimulation, and inhibition of third party peripheral blood mononuclear cell proliferation in vitro. The primary end point measured was safety and tolerability; clinical response was assessed as a secondary endpoint. Results: All patients tolerated the mesenchymal stromal cell infusion well and no dose limiting toxicity was seen. Seven patients had serious adverse events of which five were hospitalisations for Crohn's disease flare. Two of these serious adverse events were possibly related to the mesenchymal stromal cells infusion. Five subjects showed clinical response 2 weeks after the infusion. Mesenchymal stromal cell phenotype, cytokine responsiveness, and peripheral blood mononuclear cell proliferation blockade were not different among the patients. Conclusion: Single infusion of fresh autologous bone marrow mesenchymal stromal cells propagated ex vivo using human platelet lysate‐supplemented media was safe and feasible at intravenous doses of up to 10 million cells/kg BW in patients with Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622
François, M., Copland, I. B., Yuan, S., Romieu-Mourez, R., Waller, E. K., & Galipeau, J. (2012) · Cytotherapy · doi:10.3109/14653249.2011.623691 · Cited by 375
Self-citationChinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266 · cited 1×
“PBMCs were cultured at 500 000 cells/well in a 24 well-plate with cultured 10% FBS RPMI and were stimulated using anti-CD3/anti-CD28 Dyna beads (Invitrogen Carlsbad, CA, USA) in the presence and absence of mesenchymal stromal cells at the indicated ratios, Co-culture of mesenchymal stromal cells and T cells for prolif…”
MethodSelf-citationChinnadurai, R., Garcia, M. A., Sakurai, Y., Lam, W. A., Kirk, A. D., Galipeau, J., & Copland, I. B. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.05.003 · Cited by 139
Self-citation
Cited by
Ethical and Safety Issues of Stem Cell-Based Therapy
Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.21666 · Cited by 876
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
Regmi, S., Pathak, S., Kim, J. O., Yong, C. S., & Jeong, J.-H. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.04.002 · Cited by 314
The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity
Zhou, Y., Yamamoto, Y., Xiao, Z., & Ochiya, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071025 · Cited by 303
“[120] MS 10 13–26 months autogenous BM MSCs 8.”
BackgroundForbes, S., Bond, A. R., Thirlwell, K. L., Burgoyne, P., Samuel, K., Noble, J., Borthwick, G., Colligan, D., McGowan, N. W. A., Lewis, P. S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5907 · Cited by 54
Metadata
- Authors
- Dhere, T., Copland, I., Garcia, M., Chiang, K. Y., Chinnadurai, R., Prasad, M., Galipeau, J., & Kugathasan, S.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-07-07
- Volume
- 44
- Issue
- 5
- Pages
- 471-481
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2460795485
- Cited by
- 109
- References
- 4
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.